One shot may replace hours of infusion for heart attack care

NCT ID NCT01080638

Terminated Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single dose of the drug abciximab given directly into the heart artery works as well as the standard approach of a dose into a vein followed by a 12-hour infusion. The goal was to reduce heart muscle damage in people having their first non-ST elevation heart attack. The trial was terminated early, so results are incomplete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abciximab
What this could lead to: If it works, this could simplify treatment for certain heart attacks by using a single injection instead of a long infusion.
What could go wrong: The trial was terminated early, so results are limited. It only included first-time heart attack patients, so findings may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOPLASTY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute subendocardial myocardial infarction myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANGIOPLASTY MYOCARDIAL INFARCTION

Contacts and locations

Locations

Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.